Erratum: Phase II Study of ¹⁷⁷ Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers

Frank I. Lin

Jaydira Del Rivero

Jorge A. Carrasquillo

Abhishek Jha

Joy Zou

Inna Shamis

Sara Talvacchio

Baris Turkbey

2Molecular Imaging Branch, NCI, Center for Cancer Research, NIH, Bethesda, United States

Erich P. Huang

Joanna Shih

Joanna Klubo-Gwiezdzinska

Esther Mena

1National Cancer Institute, Lymphoid Malignancies Branch, Bethesda, United States

Liza Lindenberg

National Institutes of Health, Bethesda, MD

Yating Teng

Freddy E. Escorcia

Christopher H. Crane, MD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Theodore S. Hong, MD, FASCO, Harvard Medical School, Boston, Massachusetts; Freddy E. Escorcia, MD, PhD, Laboratory of Molecular Radiotherapy, National Institutes of Health, Bethesda, MD; and Laura A. Dawson, MD, Department of Radiation Oncology, University of Toronto, Toronto, Canada, Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Clara Chen

National Institutes of Health, Bethesda, MD

Peter Herscovitch

Corina Millo

Peter L. Choyke

Karel Pacak